Výsledky vyhledávání - "Joel Salla Fortuny"

Figure S1 from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Autor: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

Supplementary Figure 1: Microvessel confocal staining broken down by fluorescence channel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a157e7aab0fba6805e9a15ee8e9edbe
https://doi.org/10.1158/1078-0432.22475901

Zobrazit plný text záznamu

Supplementary Data from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Supplementary material

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542a66c4c343909e26d1145640c2e8e5
https://doi.org/10.1158/1078-0432.22475895.v1

Zobrazit plný text záznamu

Data from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Purpose:We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3f985d5e8e7524e5de28637a2d268
https://doi.org/10.1158/1078-0432.c.6529209.v1

Zobrazit plný text záznamu

Figure S2 from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Supplementary Figure 2: Pharmacodynamic endpoints: intra-tumor VEGF levels and microvessel density.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025dbe91e1566794e14d166f3844e781
https://doi.org/10.1158/1078-0432.22475898.v1

Zobrazit plný text záznamu

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

Autor: Miguel Quintela-Fandino, Juan Antonio Guerra, Juan V. Apala, María Gion, Francisca Mulero, Antonio Lopez-Alonso, Alfonso Cortés-Salgado, Diego Malón, Manuel Muñoz, Javier Cortes, Ariadna Gasol Cudós, Serafin Morales, Joel Salla Fortuny, Eduardo Caleiras, Luis Manso, Silvana Mouron

Publikováno v: Clinical Cancer Research. 26:35-45

Purpose: We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1518fa51a7c103c4c3dc49118f530580
https://doi.org/10.1158/1078-0432.ccr-19-2023

Zobrazit plný text záznamu

Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

Autor: Antonieta Salud-Salvia, Diego Marquez-Medina, Joel Salla-Fortuny

Publikováno v: Clinical and Translational Oncology. 14:891-895

The gamma-delta (γδ) T-cells are a subset of T-lymphocytes characterized by the presence of a surface antigen recognition complex type 2. Those γδ T-cells represent 2-5 % of peripheral T-cells only, but they are common in organs and mucosae, acti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74ca9245a9e5f3443340aee50e4dccfe
https://doi.org/10.1007/s12094-012-0935-7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání